Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Coherus Oncology Chief Financial Officer granted repriced options
Coherus Oncology, Inc. reported that its Chief Financial Officer, Bryan J. McMichael, received several grants of stock options on May 29, 2026, each with an exercise price of $1.59 per share and expirations on May 29, 2036. These options cover multiple blocks, including grants for 100,000, 30,000, 25,000, 25,000, 25,000, and 15,000 shares of common stock as compensation.
On the same date, the company recorded dispositions of earlier stock options back to the issuer, in matching share amounts but with higher exercise prices ranging from $5.44 to $14.76 per share, reflecting a stockholder-approved option repricing for options previously priced at or above $5. No open‑market purchases or sales of common stock were reported in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
McMichael Bryan J
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 100,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 100,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null)
Footnotes (1)
- The option is fully vested and exercisable. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from September 7, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 27, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged. On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.
Key Figures
Largest new option grant: 100,000 options
New exercise price: $1.59 per share
Highest cancelled strike: $14.76 per share
+3 more
6 metrics
Largest new option grant
100,000 options
Grant to CFO on May 29, 2026
New exercise price
$1.59 per share
Repriced stock options approved May 29, 2026
Highest cancelled strike
$14.76 per share
Option disposition to issuer on May 29, 2026
Option expiration
May 29, 2036
New grants’ expiration date
Cancelled grant size
100,000 options
Disposition to issuer at $14.76 strike
Other grant blocks
30,000; 25,000; 25,000; 25,000; 15,000 options
Additional CFO option grants at $1.59 strike
Key Terms
stock option repricing, Disposition to issuer, vesting, exercise price, +1 more
5 terms
stock option repricing financial
"stockholders approved an option repricing at an exercise price of $1.59 per share"
Disposition to issuer financial
"transaction_code_description": "Disposition to issuer""
vesting financial
"shares subject to the option vest and become exercisable as to 1/48th of the total"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"an option repricing at an exercise price of $1.59 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
stock option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
FAQ
What did Coherus Oncology (CHRS) report in this Form 4 for its CFO?
Coherus Oncology reported that CFO Bryan J. McMichael received multiple grants of stock options on May 29, 2026 at an exercise price of $1.59 per share, while older, higher-priced options in the same share amounts were returned to the issuer as part of an approved repricing.
How many Coherus Oncology (CHRS) options were granted to the CFO and at what price?
The CFO received several stock option grants covering blocks of 100,000, 30,000, 25,000, 25,000, 25,000, and 15,000 shares of Coherus Oncology common stock, each with an exercise price of $1.59 per share and an expiration date of May 29, 2036, as compensation awards.
What is the Coherus Oncology (CHRS) stock option repricing mentioned in the Form 4?
On May 29, 2026, Coherus Oncology stockholders approved an option repricing to reset certain employee stock options with exercise prices at or above $5 to $1.59 per share, while keeping all other terms unchanged, including vesting schedules and service-based conditions for the affected options.
What does “Disposition to issuer” mean in the Coherus Oncology (CHRS) Form 4?
“Disposition to issuer” indicates previously granted stock options were returned to Coherus Oncology itself, rather than sold in the market. In this filing, those dispositions cancel higher-strike options with exercise prices from $5.44 to $14.76 per share as part of the approved option repricing.
How do the vesting terms work for the repriced Coherus Oncology (CHRS) options?
Footnotes explain that underlying shares for certain options vest in equal monthly installments of 1/48th of the total from specified start dates, such as September 7, 2022, January 4, 2023, and March 27, 2023, contingent on the CFO’s continued service with Coherus Oncology on each vesting date.